TAKEDA PHARMACEUTICAL CO LTD current report, Q3 FY2023

Full document

Takeda Pharmaceutical Co Ltd: Q1 FY2024 Financial Summary

Business Context and Reporting Period

This Form 6-K summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the three-month period ended June 30, 2023 (Q1 of Fiscal Year 2024). The report was filed on July 27, 2023. Takeda operates globally with key business areas in Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Immunology, Oncology, and Neuroscience.

Key Financial Metrics

Metric Q1 FY2024 (Actual) Q1 FY2023 (Prior Year) Change (AER)
Revenue JPY 1,058.6 billion JPY 972.5 billion +8.9%
Operating Profit JPY 168.6 billion JPY 150.5 billion +12.0%
Profit Before Tax JPY 135.0 billion JPY 155.5 billion -13.1%
Net Profit JPY 89.4 billion JPY 105.0 billion -14.9%
Basic EPS JPY 57.51 JPY 67.94 -15.4%
Core Operating Profit JPY 326.3 billion JPY 319.1 billion +2.3%
Core EPS JPY 150 JPY 145 +3.5%

Balance Sheet and Cash Flow

  • Total Assets: JPY 14,792.7 billion (as of June 30, 2023), an increase of JPY 835.0 billion from the prior fiscal year-end, primarily due to foreign currency translation effects on Goodwill, Intangible Assets, and Property, Plant, and Equipment.
  • Total Equity: JPY 6,921.7 billion, with an equity ratio of 46.8%.
  • Debt: Total Bonds and Loans stood at JPY 4,747.1 billion. This includes JPY 4,006.3 billion in bonds and JPY 740.8 billion in loans. The increase was driven by foreign currency translation and the issuance of JPY 150.0 billion in commercial paper in June 2023.
  • Cash Flow:
    • Net cash from operating activities: JPY 92.4 billion.
    • Net cash used in investing activities: JPY 266.5 billion (driven by intangible asset acquisitions, including TAK-279 from Nimbus Therapeutics).
    • Net cash used in financing activities: JPY 57.8 billion.
    • Cash and cash equivalents at period end: JPY 316.4 billion.

Material Changes and Drivers

Revenue Growth: Revenue increased 8.9% on an Actual Exchange Rate (AER) basis and 3.7% on a Constant Exchange Rate (CER) basis. Growth was driven by favorable foreign exchange rates and momentum in key business areas, offset by a decline in Oncology due to generic erosion and lower COVID-19 vaccine revenue.

Profitability: While Operating Profit rose 12.0% (AER), Net Profit declined 14.9% (AER). The decline in Net Profit was primarily due to a significant swing in finance results, moving from net finance income of JPY 5.5 billion in the prior year to net finance expenses of JPY 33.1 billion in the current period. This was caused by a decrease in finance income from prior equity method company acquisitions.

Segment Performance:

  • PDT Immunology: Revenue surged 31.5% (AER) due to strong global demand for immunoglobulin and albumin products.
  • Neuroscience: Revenue grew 24.3% (AER), led by VYVANSE/ELVANSE and ADDERALL XR, benefiting from generic shortages of competitor products in the U.S.
  • Oncology: Revenue fell 6.0% (AER), heavily impacted by the loss of exclusivity for VELCADE.

Guidance, Outlook, and Risks

Full Year Forecast (FY Ending March 31, 2024): Takeda has not revised its full-year forecast announced in May 2023.

  • Revenue: JPY 3,840.0 billion (-4.7% vs prior year).
  • Operating Profit: JPY 349.0 billion (-28.8% vs prior year).
  • Net Profit: JPY 142.0 billion (-55.2% vs prior year).
  • Core Operating Profit: JPY 1,015.0 billion (-14.6% vs prior year).

Management Guidance (CER Basis):

  • Core Revenue: Low-single-digit % decline.
  • Core Operating Profit: Low-10s % decline.
  • Core EPS: Low-20s % decline.

Risks and Contingencies:

  • Loss of Exclusivity (LOE): The forecast assumes approximately JPY 330.0 billion in revenue loss from LOEs, including AZILVA in Japan (June 2023) and VYVANSE in the U.S. (August 2023).
  • Foreign Exchange: Significant volatility in the Japanese yen impacts reported results. Management guidance is based on Constant Exchange Rates to mitigate this.
  • Investments: Significant cash outflows are expected for the acquisition of TAK-279 (Nimbus) and in-licensing of fruquintinib (HUTCHMED).

Investor Verification Checklist

  • Finance Expense Volatility: Verify the sustainability of the JPY 33.1 billion net finance expense, which was a primary driver of the net profit decline compared to the prior year's finance income.
  • LOE Impact Timing: Confirm the actual revenue impact of the VYVANSE loss of exclusivity in the U.S. scheduled for August 2023.
  • Core vs. Reported Metrics: Note the divergence between reported Net Profit (-14.9%) and Core Operating Profit (+2.3%), driven by non-operating finance items and amortization.
  • Cash Burn on Acquisitions: Monitor cash flow usage related to the JPY 223.3 billion acquisition of intangible assets (TAK-279 and HUTCHMED deals) and its impact on liquidity.
  • Dividend Policy: Verify the projected total annual dividend of JPY 188.00 per share against the reduced net profit forecast.